Anebulo Pharmaceuticals Stock Fundamentals
| ANEB Stock | USD 1.40 0.06 4.11% |
Anebulo Pharmaceuticals fundamentals help investors to digest information that contributes to Anebulo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Anebulo Stock. The fundamental analysis module provides a way to measure Anebulo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anebulo Pharmaceuticals stock.
At present, Anebulo Pharmaceuticals' Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 158.8 K, whereas Depreciation And Amortization is forecasted to decline to about 245.4 K. Anebulo | Select Account or Indicator |
Anebulo Pharmaceuticals Company Shares Owned By Insiders Analysis
Anebulo Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Anebulo Pharmaceuticals Shares Owned By Insiders | 64.22 % |
Most of Anebulo Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anebulo Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 64% of Anebulo Pharmaceuticals are shares owned by insiders. This is 323.06% higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Anebulo Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Anebulo Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Anebulo Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Anebulo Pharmaceuticals competition to find correlations between indicators driving Anebulo Pharmaceuticals's intrinsic value. More Info.Anebulo Pharmaceuticals is rated second in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At present, Anebulo Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Anebulo Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Anebulo Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anebulo Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Anebulo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Anebulo Pharmaceuticals by comparing valuation metrics of similar companies.Anebulo Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Anebulo Fundamentals
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 34.9 M | ||||
| Shares Outstanding | 25.93 M | ||||
| Shares Owned By Insiders | 64.22 % | ||||
| Shares Owned By Institutions | 28.18 % | ||||
| Number Of Shares Shorted | 10.76 K | ||||
| Price To Book | 19.12 X | ||||
| EBITDA | (8.05 M) | ||||
| Net Income | (8.2 M) | ||||
| Cash And Equivalents | 14.55 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 260.58 K | ||||
| Current Ratio | 30.40 X | ||||
| Book Value Per Share | 0.15 X | ||||
| Cash Flow From Operations | (8.09 M) | ||||
| Short Ratio | 1.94 X | ||||
| Earnings Per Share | (0.32) X | ||||
| Target Price | 6.0 | ||||
| Beta | -1.01 | ||||
| Market Capitalization | 42.79 M | ||||
| Total Asset | 4.07 M | ||||
| Retained Earnings | (65.4 M) | ||||
| Working Capital | 3.25 M | ||||
| Net Asset | 4.07 M |
About Anebulo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anebulo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anebulo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anebulo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:Check out Anebulo Pharmaceuticals Piotroski F Score and Anebulo Pharmaceuticals Altman Z Score analysis. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Return On Assets (0.66) | Return On Equity (1.14) |
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.